Company
Dimerix Ltd
ASX:DXB
Dimerix Ltd is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. The company's lead candidate is in Phase 3 clinical trials for a rare type of kidney disease.
22 stories
Hardware & electrical equipment
ShareRoot increases the Social Science takings amid MediaConsent interest
The consumer data security provider is aiming to grow revenue and reduce spending in the coming year.
Dimerix to lift cash following visit to World Congress for Clinical Trials in Diabetes
The halt will remain in place until Tuesday 5th December 2017.
Dimerix appoints Kathy Harrison inaugural full time CEO
Dimerix if focused on clinical trials for Chronic Kidney Disease.
Dimerix Ltd's valuation more than doubles after Kathy Harrison delivers results
Dimerix's valuation has doubled in the past month.
Dimerix Ltd's shares rally on positive results from clinical trial
The trial meets the primary safety endpoint and demonstrates encouraging efficacy.
Dimerix Ltd to reveal Phase 2 trial results on Chronic Kidney Disease
The halt will remain in place until Thursday 13th July 2017.
Dimerix hosts key U.S. meetings ahead of final clinical data
Dimerix has received Orphan Drug Designation for the use of DMX-200.
Dimerix: Access latest PPT from Proactive's CEO Sessions
Kathy Harrison talked pending milestone news with investors.
Aspire Mining [JOHN TO UPDATE] Proactive's Spotlight CEO Sessions
Find out more from David Paull at Proactive's CEO Spotlight Sessions.
Dimerix brings Phase II clinical trials to Proactive's Spotlight CEO Sessions
Find out more from Kathy Harrison at Proactive's CEO Spotlight Sessions.
Novogen [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Dr James Garner at Proactive's CEO Sessions.
Proteomics International to outline pathway to market at Proactive's CEO Sessions
Find out more from Richard Lipscombe at Proactive's CEO Sessions.
Southern Gold brings gold production to Proactive's Spotlight CEO Sessions
Find out more from Simon Mitchell at Proactive's CEO Sessions.
Intermin Resources [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Jon Price at Proactive's CEO Spotlight Sessions.
Dimerix receives cash injection from tax refund
Dimerix Limited has recently received an R&D tax refund.
Dimerix to outline capital raising
Dimerix (ASX:DXB) has been granted a trading halt by the ASX.